Literature DB >> 22677714

Ivermectin binding sites in human and invertebrate Cys-loop receptors.

Timothy Lynagh1, Joseph W Lynch.   

Abstract

Ivermectin is a gold standard antiparasitic drug that has been used successfully to treat billions of humans, livestock and pets. Until recently, the binding site on its Cys-loop receptor target had been a mystery. Recent protein crystal structures, site-directed mutagenesis data and molecular modelling now explain how ivermectin binds to these receptors and reveal why it is selective for invertebrate members of the Cys-loop receptor family. Combining this with emerging genomic information, we are now in a position to predict species sensitivity to ivermectin and better understand the molecular basis of ivermectin resistance. An understanding of the molecular structure of the ivermectin binding site, which is formed at the interface of two adjacent subunits in the transmembrane domain of the receptor, should also aid the development of new lead compounds both as anthelmintics and as therapies for a wide variety of human neurological disorders.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677714     DOI: 10.1016/j.tips.2012.05.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  32 in total

1.  Ivermectin activates GIRK channels in a PIP2 -dependent, Gβγ -independent manner and an amino acid residue at the slide helix governs the activation.

Authors:  I-Shan Chen; Michihiro Tateyama; Yuko Fukata; Motonari Uesugi; Yoshihiro Kubo
Journal:  J Physiol       Date:  2017-07-30       Impact factor: 5.182

Review 2.  Nicotinic acetylcholine receptors at the single-channel level.

Authors:  Cecilia Bouzat; Steven M Sine
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

3.  Mosquitocidal properties of IgG targeting the glutamate-gated chloride channel in three mosquito disease vectors (Diptera: Culicidae).

Authors:  Jacob I Meyers; Meg Gray; Brian D Foy
Journal:  J Exp Biol       Date:  2015-05-15       Impact factor: 3.312

4.  Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae.

Authors:  Jacob I Meyers; Meg Gray; Wojtek Kuklinski; Lucas B Johnson; Christopher D Snow; William C Black; Kathryn M Partin; Brian D Foy
Journal:  J Exp Biol       Date:  2015-05-15       Impact factor: 3.312

5.  A predicted binding site for cholesterol on the GABAA receptor.

Authors:  Jérôme Hénin; Reza Salari; Sruthi Murlidaran; Grace Brannigan
Journal:  Biophys J       Date:  2014-05-06       Impact factor: 4.033

6.  Niosomal versus nano-crystalline ivermectin against different stages of Trichinella spiralis infection in mice.

Authors:  Dalia A Elmehy; Marwa A Hasby Saad; Gamal M El Maghraby; Mona F Arafa; Nema A Soliman; Heba H Elkaliny; Dina I Elgendy
Journal:  Parasitol Res       Date:  2021-05-04       Impact factor: 2.289

Review 7.  Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin.

Authors:  I-Shan Chen; Yoshihiro Kubo
Journal:  J Physiol       Date:  2017-11-09       Impact factor: 5.182

8.  Orthosteric and Allosteric Activation of Human 5-HT3A Receptors.

Authors:  Noelia Rodriguez Araujo; Camila Fabiani; Albano Mazzarini Dimarco; Cecilia Bouzat; Jeremías Corradi
Journal:  Biophys J       Date:  2020-09-02       Impact factor: 4.033

9.  Positive and Negative Allosteric Modulation of an α1β3γ2 γ-Aminobutyric Acid Type A (GABAA) Receptor by Binding to a Site in the Transmembrane Domain at the γ+-β- Interface.

Authors:  Selwyn S Jayakar; Xiaojuan Zhou; Pavel Y Savechenkov; David C Chiara; Rooma Desai; Karol S Bruzik; Keith W Miller; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

10.  New GABA/glutamate receptor target for [³H]isoxazoline insecticide.

Authors:  Pablo García-Reynaga; Chunqing Zhao; Richmond Sarpong; John E Casida
Journal:  Chem Res Toxicol       Date:  2013-03-12       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.